Skip to main content
. Author manuscript; available in PMC: 2024 Oct 30.
Published in final edited form as: Stroke. 2024 Oct 21;55(11):2705–2715. doi: 10.1161/STROKEAHA.124.048264

Figure 6: Neurodevelopmental outcomes following caffeine or azithromycin treatment:

Figure 6:

A, we assessed composite and individual outcomes consisting of motor function, feeding and activity and assigned a severity score. The summary graphs picture the relationship of LD- and HD-caffeine to placebo animals. LD-caffeine-treated group, n=19, blue; HD-caffeine treated group- red, n=8; Placebo- black, n=53, Azithromycin-green, n=21, Control- purple, n=12. B, The correlation matrix depicts Spearman’s correlation coefficients of selected study parameters with combined neurological outcomes scores on day 6 after UCO that reached statistical significance (p<0.05).